FUJIFILM VisualSonics launches first Ultra High Frequency clinical ultrasound imaging system


FUJIFILM VisualSonics Inc., a world leader in ultra high frequency ultrasound imaging systems and subsidiary of FUJIFILM SonoSite, Inc., announces CE mark for the Vevo® MD, the world’s first Ultra High Frequency (UHF) clinical ultrasound system. With multiple successes in preclinical research over the last decade, today marks a major milestone for FUJIFILM VisualSonics as it expands into the clinical market.

“As the undisputed leader in ultra high frequency imaging systems, FUJIFILM VisualSonics once again advances the field of ultrasound with the launch of the Vevo MD,” said Masayuki Higuchi, president & CEO, FUJIFILM SonoSite, Inc. “We are proud to be the first to bring to market this exciting innovation that is sure to have high impact on the medical imaging community while expanding the product portfolio of FUJIFILM SonoSite.”

The Vevo MD is truly a unique ultrasound system, as it operates at much higher frequencies than any conventional ultrasound system currently available. Along with the Vevo MD system, FUJIFILM VisualSonics also introduces the UHF Series of transducers. This patented transducer technology is capable of operating in a range of frequencies up to 70 MHz, a tremendous increase in resolution compared to conventional ultrasound systems.

“The Vevo MD allows medical professionals to see what they have never seen before—unparalleled image resolution down to 30 micrometers. This is less than half the size of a grain of sand,” said Renaud Maloberti, vice president & general manager of FUJIFILM VisualSonics. “Imagine the great potential this technology has across unexplored applications to visualize the smallest, highly detailed anatomy in a way that has never been done before.”

“We believe this technology has a role to play in a range of clinical application areas from neonatology, vascular, musculoskeletal, dermatology, or other small parts that are within the first 3 cm of the body,” said Andrew Needles, director of marketing at FUJIFILM VisualSonics.“We also know that there are new and interesting areas to be discovered. The Vevo MD gives us and our users the opportunity to make those discoveries together.”

The Vevo MD is now commercially available with CE mark in the majority of European Union countries. For more information and contact details please visit www.vevomd.com or contact FUJIFILM VisualSonics at www.visualsonics.com.



Philips starts shipping Lumify in the U.S., an app-based ultrasound



Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) announced that Lumify, a smart device ultrasound solution, is available for purchase by licensed healthcare providers or organizations in the U.S. Lumify is offered as part of a novel subscription model unique to the industry. From Philips’ online portal, users will be able to order transducers, manage flexible subscriptions and access Philips’ support, training and IT services through the new offering. Philips’ new ultrasound digital health approach connects off-the-shelf compatible smart devices, a mobile application, advanced ultrasound transducer technology, integrated IT and support services to help healthcare providers improve patient care and reduce costs.

Since debuting the smart device ultrasound concept in 2014, Philips has enhanced the solution for more clinical uses including acute care and office practice. As a comprehensive solution, Lumify extends the benefits of ultrasound to more places by leveraging cloud-enabled and tablet technology, and bringing connectivity, flexibility and mobility into the hands of more healthcare providers.

Continue reading here


DBAC Ultrasound Cuff to Stop Bleeding

DBAC ultrasound

Since 2008, Siemens and University of Washington have been working on a very ambitious project. DBAC (Deep Bleeder Acoustic Coagulation). Funded by DARPA (Defense Advanced Research Project Agency), the goal is to use HIFU (High Intensity Focused Ultrasound) to stop bleeding in deep vessels.  Here they report the latest findings in this two part paper.

Part I: development and in vitro testing of a research prototype cuff system

Part II: in vivo testing of a research prototype system




Handheld ultrasound Signostics receives $35 million from private investor KKR

handheld ultrasound


CLOVELLY PARK, SOUTH AUSTRALIA (November 16, 2015) – Signostics, a start-up innovator in the field of highly miniaturized ultrasound technology, today announced a private investment of $35 million dollars from KKR, a leading global investment firm.

Since launching its first product in 2009, Signostics has remained focused on the development of handheld ultrasound technology. The new funding by KKR will allow Signostics to pursue cutting-edge medical innovations and to expand and accelerate global marketing and distribution for new products. Prior to this transaction, Signostics re-domiciled from Australia to become a Delaware-based corporation with newly-established headquarters in Kirkland, Washington.

“KKR offers us the privilege of working with a highly regarded long-term capital partner which will enable us to create next-level innovations and beyond, aimed at greater disruption and democratization of the global ultrasound market,” said Kevin Goodwin, Chief Executive Officer of Signostics who joined the company earlier this year. “We feel very fortunate to have gained the support of KKR as we set out to build on our work in this field over the last decade.”

Continue reading here


World first: blood-brain barrier opened non-invasively to deliver chemotherapy

Blood-Brain Barrier

Toronto, ON (November 8, 2015) – Sunnybrook scientists made history this week as they used focused ultrasound to non-invasively breach the blood-brain barrier and more effectively deliver chemotherapy into the brain tumour of a patient.

Each person has a protective barrier that normally restricts the passage of substances from the bloodstream into the brain protecting it from toxic chemicals.

“The blood-brain barrier (BBB) has been a persistent obstacle to delivering valuable therapies to treat disease such as tumours,” says Dr. Todd Mainprize, principal investigator of the study and Neurosurgeon in the Hurvitz Brain Sciences Program at Sunnybrook Health Sciences Centre.

“We are encouraged that we were able to temporarily open this barrier in a patient to deliver chemotherapy directly to the brain tumour.”

The research team infused a chemotherapy drug, then tiny, microscopic bubbles, into the bloodstream of a patient with a malignant brain tumour. The microbubbles are smaller than red blood cells and pass harmlessly through the circulation. The researchers then used state-of-the-art MRI-guided focused low-intensity ultrasound (sound waves) to target blood vessels in the BBB area near the tumour. The waves repeatedly compress and expand the microbubbles, causing them to vibrate and loosen tight junctions of the cells comprising the BBB. Once the barrier was opened, the chemotherapy flowed through and deposited into the targeted regions.

“Some of the most exciting and novel therapeutics for the treatment of malignant brain tumours are not able to reach the tumour cells because of the blood brain barrier. This technique will open up new opportunities to deliver potentially much more effective treatments to the targeted areas,” says Dr. Todd Mainprize, also an Assistant Professor in the Division of Neurosurgery at University of Toronto.

Dr. Kullervo Hynynen, Director of Physical Sciences at Sunnybrook Research Institute, worked with industry partner Insightec for almost two decades to develop the technology and bring it to a clinic-ready state. “The success of this case is gratifying,” he says. “My hope now is that many patients will eventually benefit from it.”

Less than 24 hours after breaching the blood brain barrier, the tumour and some surrounding tissues were surgically removed and sent to pathology to measure differences in the concentration of chemotherapy that deposited in the area treated by the focused ultrasound and the area not treated.

“Breaching this barrier opens up a new frontier in treating brain disorders,” says Dr. Neal Kassell, chairman of the Focused Ultrasound Foundation. “We are encouraged by the momentum building for the use of focused ultrasound to non-invasively deliver therapies for a number of brain disorders.”

The success of this research opens up the potential for delivering drug therapies to parts of the brain protected by the blood brain barrier, including researching treatments for patients with various kinds of brain tumours, Alzheimer’s disease, and some psychiatric conditions.

“This is a very important step in the development of MR-guided focused ultrasound technology,” says Eyal Zadicario, VP R&D and Director of Neuro Programs at Insightec. “We continue to push the technology into new clinical applications that can have significant impact where it matters most – to patients.”

This case was the first of up to 10 participants in this study, which is testing for feasibility, safety and preliminary efficacy. The participants are those already scheduled for traditional neurosurgery to remove parts of their brain tumour.

This study is funded by the Focused Ultrasound Foundation. The research equipment is funded by the Canada Foundation for Innovation and Ontario Ministry of Research and Innovation, with support from the Bombardier Foundation. The research has also received significant support from the Canadian Institutes of Health Research and National Institutes of Health. Dr. Hynynen holds the Canada Research Chair in Imaging Systems and Image-Guided Therapeutics. The focused ultrasound apparatus and technology are Insightec’s Exablate Neuro System.

Media contact:

Nadia Norcia Radovini, nadia.radovini@sunnybrook.ca, (416) 480-4040

See original post and video here



Heat-activated ‘grenade’ to target cancer

Researchers have developed cancer drug-packed ‘grenades’ armed with heat sensitive triggers, allowing for treatment to be targeted directly at tumours, according to two studies due to be presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.

The team based at The University of Manchester has been developing liposomes – small, bubble-like structures built out of cell membrane that are used as packages to deliver molecules into cells – to carry drugs into cancer cells. The challenge, as with any treatment, is to direct the liposomes and their payload directly to tumours while sparing healthy tissue.

… Read more here


InvenSense Announces Ultrasound Fingerprint Touch Sensor

SAN JOSE, Calif.–(BUSINESS WIRE)–Oct. 28, 2015– InvenSense, Inc. (NYSE:INVN), the leading provider of MEMS sensor platforms, today announced it has released for OEM review UltraPrint, its ultrasonic fingerprint imaging solution, manufactured on the proprietary InvenSense CMOS-MEMS Platform (ICMP), offering ramp to production in calendar year 2017. As the world’s largest fabless MEMS SOC innovator and source for the eutectically bonded ICMP, InvenSense ships, on average, over twelve million motion or audio sensor SOCs each week to leading global mobile and IoT OEMs.

… Read more here


Globalsound Solutions Receives 2015 Best of Burlington Award

Globalsound Solutions Receives 2015 Best of Burlington Award

Globalsound Solutions receives Best of Burlington award in Engineering Service category


Globalsound Solutions, Inc Receives 2015 Best of Burlington Award

BURLINGTON October 21, 2015 — Globalsound Solutions, Inc has been selected for the 2015 Best of Burlington Award in the Engineering Services category by the Burlington Award Program.

Each year, the Burlington Award Program identifies companies that we believe have achieved exceptional marketing success in their local community and business category. These are local companies that enhance the positive image of small business through service to their customers and our community. These exceptional companies help make the Burlington area a great place to live, work and play.

Various sources of information were gathered and analyzed to choose the winners in each category. The 2015 Burlington Award Program focuses on quality, not quantity. Winners are determined based on the information gathered both internally by the Burlington Award Program and data provided by third parties.

About Burlington Award Program

The Burlington Award Program is an annual awards program honoring the achievements and accomplishments of local businesses throughout the Burlington area. Recognition is given to those companies that have shown the ability to use their best practices and implemented programs to generate competitive advantages and long-term value.

The Burlington Award Program was established to recognize the best of local businesses in our community. Our organization works exclusively with local business owners, trade groups, professional associations and other business advertising and marketing groups. Our mission is to recognize the small business community’s contributions to the U.S. economy.

SOURCE: Burlington Award Program

Burlington Award Program
Email: PublicRelations@local-best.com
URL: http://www.local-best.com


1 2